What is the mechanism of action of sorafenib?

Mechanism of action Sorafenib treatment induces autophagy, which may suppress tumor growth. Based on its 1,3-disubstituted urea structure, Sorafenib is also a potent soluble epoxide hydrolase inhibitor and this activity likely reduces the severity of its adverse effects.

What type of drug is sorafenib?

Sorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.

Is sorafenib a chemotherapy drug?

Sorafenib (Nexavar) Chemotherapy Drug Information.

Is sorafenib a tyrosine kinase inhibitor?

Sorafenib (BAY 43-9006, Nexavar®) is an oral multiple tyrosine kinase inhibitor. Main targets are receptor tyrosine kinase pathways frequently deregulated in cancer such as the Raf-Ras pathway, vascular endothelial growth factor (VEGF) pathway, and FMS-like tyrosine kinase 3 (FLT3).

How long is sorafenib Effective?

The median duration of sorafenib treatment was 5.4 (95% CI 4.5–6.0; range 1.0–70) months.

What is sorafenib target?

The oral multikinase inhibitor sorafenib targets the Raf serine/threonine kinases (Raf-1, wild-type B-Raf, and oncogenic B-Raf V600E) and receptor tyrosine kinases (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, Flt-3, and c-Kit) implicated in tumorigenesis and tumor progression.

How long can you take sorafenib?

Median overall survival was 26.1 months with overall 6- and 12-month survival rates of 92.1 and 85%, respectively. Median time to radiological progression was 8 months. The progression-free rate was 64.3%.

How effective is sorafenib?

Sorafenib was associated with a nonsignificant reduction in mortality at 3 months (44% versus 51%; adjusted risk ratio, 0.88 [95% CI, 0.72-1.07]), but no reduction thereafter.

Can sorafenib shrink tumors?

Not only that, MRI scans showed rapid shrinkage of the tumor size during early sorafenib treatment (39.8% in week 5 and by 96.9% in week 15), which indicated that rapid tumor shrinking on the imaging may be another indicator of the therapeutic effects of sorafenib.

Is sorafenib FDA approved?

The U.S. Food and Drug Administration (FDA) on November 19 announced that it has approved sorafenib (Nexavar) for use in patients with hepatocellular carcinoma (HCC) when the cancer is inoperable.

When can I stop taking sorafenib?

Sorafenib was stopped in cases with severe side effects that recurred and impaired quality of life when reintroducing the dose of 400 mg/day, when toxicity was associated with tumor progression, or when the tumor progressed in the absence of symptomatic progression if a second-line trial was available.

Sorafenib is a Kinase Inhibitor. The mechanism of action of sorafenib is as a Protein Kinase Inhibitor. Sorafenib is an oral multi-kinase inhibitor that is used in the therapy of advanced renal cell, liver and thyroid cancer.

What kind of CYP isoenzymes does sorafenib inhibit?

In vitro studies using human hepatic microsomes indicate that sorafenib inhibits CYP isoenzymes 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4; however, sorafenib does not appear to alter exposure to dextromethorphan (a CYP2D6 substrate), midazolam (a CYP3A4 substrate), or omeprazole (a CYP2C19 substrate).

What are the risks of bleeding from sorafenib?

Possible increased risk of bleeding. In clinical studies, bleeding (regardless of causality) was reported in 15.3 or 8.2% of patients receiving sorafenib or placebo, respectively.

What kind of cancer can Sorafenib tosylate treat?

Sorafenib tosylate is approved to treat: Hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery. Renal cell carcinoma (a type of kidney cancer) that is advanced. Thyroid cancerin certain patients with progressive, recurrent, or metastaticdisease that does not respondto treatment with radioactive iodine.